GlassScriptPhysician profile
Joshua Scott Simmons
NPI 1033987573
$1,026.41
in general payments reported to CMS, 2019-2025
22 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $682 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $231.23 | 2024-2025 | |
| Organon LLC | $203.91 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $84.20 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $81.69 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $59.79 | 2024-2025 | |
| Lundbeck LLC | $52.69 | 2024-2025 | Rexulti |
| Insulet Corporation | $30.85 | 2025 | Omnipod |
| Teva Pharmaceuticals USA, INC. | $30.46 | 2024 | Austedo Xr |
| Braeburn INC. | $29.59 | 2024 | Brixadi |
| Seqirus USA INC | $28.04 | 2024 | Fluad, Flucelvax |
| Merck Sharp & Dohme LLC | $23.87 | 2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Vanda Pharmaceuticals INC. | $18.88 | 2025 | Fanapt, Hetlioz |
| Hologic Sales and Service, LLC | $17.29 | 2024 | Thinprep 2000 Processor, Aptima |
| Xeris Pharmaceuticals, INC. | $17.07 | 2025 | Gvoke Hypopen |
| Amgen INC. | $16.78 | 2025 | Otezla, Repatha |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16.57 | 2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $15.05 | 2025 | Cologuard Collection Kit |
| Ardelyx, INC. | $14.46 | 2025 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.84 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.58 | 2024 | Jardiance |
| Novo Nordisk INC | $13.41 | 2024 | Wegovy |
| Noven Therapeutics, LLC | $13.16 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.